Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.
about
Regulation of acidification and apoptosis by SHP-1 and Bcl-2Biochemical and functional properties of somatostatin receptorsEffects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptorInactivation of raf-1 by a protein-tyrosine phosphatase stimulated by GTP and reconstituted by Galphai/o subunits.Activation of a protein tyrosine phosphatase and inactivation of Raf-1 by somatostatinResearch Resource: Real-Time Analysis of Somatostatin and Dopamine Receptor Signaling in Pituitary Cells Using a Fluorescence-Based Membrane Potential Assay.Proliferative and apoptotic responses in cancers with special reference to oral cancer.Somatostatin receptor imaging, therapy and new strategies in patients with neuroendocrine tumours.Biology of pancreatic cancerAntiangiogenic effects of somatostatin analogues.Somatostatin analogues in the treatment of endocrine tumors of the gastrointestinal tract.Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2.Lipophilization of somatostatin analog RC-160 with long chain fatty acid improves its antiproliferative and antiangiogenic activity in vitro.Treatment of hepatocellular carcinoma with octreotide: a randomised controlled studyExperimental and clinical studies with somatostatin analogue octreotide in small cell lung cancerSomatostatin binding in normal and malignant human gastrointestinal mucosa.Effects of somatostatin analogue RC-160 and bombesin/gastrin-releasing peptide antagonists on the growth of human small-cell and non-small-cell lung carcinomas in nude miceSomatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae.Analysis of somatostatin receptor subtype mRNA expression in human breast cancer.Peptide analogues alter the progression of premalignant lesions, as measured by Photofrin fluorescence.Neuropeptide growth factors.Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5.Somatostatin receptors are expressed by immature cerebellar granule cells: evidence for a direct inhibitory effect of somatostatin on neuroblast activity.Regulation of colonic apical potassium (BK) channels by cAMP and somatostatin.Review of recent advances in analytical techniques for the determination of neurotransmittersEffects of epidermal growth factor and analogues of luteinizing hormone-releasing hormone and somatostatin on phosphorylation and dephosphorylation of tyrosine residues of specific protein substrates in various tumorsRegulation of luteinizing hormone-releasing hormone receptor binding by heterologous and autologous receptor-stimulated tyrosine phosphorylation.Epidermal growth factor and related growth factors.Functional coupling of a mammalian somatostatin receptor to the yeast pheromone response pathway.Neuroendocrine factors: The missing link in non‑melanoma skin cancer (Review).Synthesis and evaluation of biodegradable PCL/PEG nanoparticles for neuroendocrine tumor targeted delivery of somatostatin analog.Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells.Tumors of the endocrine/neuroendocrine system: an overview.Somatostatin and the treatment of pancreatic cancer.Somatostatin analog SMS 201995 inhibits proliferation in human leukemia T-cell line: relevance of the adenylyl cyclase stimulation.Inhibition of the growth of Caki-I human renal adenocarcinoma in vivo by luteinizing hormone-releasing hormone antagonist Cetrorelix, somatostatin analog RC-160, and bombesin antagonist RC-3940-II.Involvement of MAP kinase and c-fos signaling in the inhibition of cell growth by somatostatin.Differences in the operational characteristics of the human recombinant somatostatin receptor types, sst1 and sst2, in mouse fibroblast (Ltk-) cells.Growth-regulatory effects of sensory neuropeptides, epidermal growth factor, insulin, and somatostatin on the non-transformed intestinal epithelial cell line IEC-6 and the colon cancer cell line HT 29.Molecular pharmacology of somatostatin receptor subtypes.
P2860
Q22010599-DE2ABE18-ABB3-406E-A242-BFA48595FE37Q28210100-07BC240D-6EA6-4E45-96F4-B940AB2358C9Q28343691-ECE0115C-F9F3-47F2-BCD1-963208DDF15DQ30468240-3D2EE05C-5DF9-4D28-802B-E74446D148F6Q30468565-0FDB2132-C1C0-4CBA-A8EE-DDA975F0F35DQ33631389-D6C284A1-0271-408B-96BD-AFB5B5B48F8DQ33888373-086B5DB8-935A-4670-B61A-B4CEAF21298CQ34117185-C894E8C6-2AE6-45BF-AED9-6DB0D0F1BB41Q34394264-3FC83E34-3BF8-4D34-B318-9481CED3C268Q34920676-9ADEA801-1AF3-42F0-AE55-D10C84965149Q35020349-904DAD02-2FD5-4E67-B0F9-1F0A28C49C66Q35106579-069AB410-0A5F-434C-BBA0-BF58ACCCF543Q35107573-6C436D87-6099-4B77-A0CE-07AF2434758EQ35349653-9D34AE50-1963-44B8-B153-7DD8988FCB86Q35993786-83821F3D-2734-4F20-895A-F46B51B02615Q35994163-20D50669-BB26-4270-8F47-FD2E94DABEFDQ36080188-3499E18C-318D-463E-BA07-638E33ED60F1Q36116318-E7527384-AA08-47BF-B7CE-27E6BF615167Q36116487-6F2D8CD8-D98E-4B0C-A095-50FB7328C2B1Q36138890-B89E1C2D-50C7-4574-80E6-C9505FB25153Q36535839-6BBD1E65-6073-44F4-95B1-70B9EC5C5783Q36566036-946A61F4-4A49-4AA0-9721-017B67D3AC55Q37246839-4F535A00-6105-4516-A9A1-6E255E813146Q37264530-86E98C3B-E6F6-4E36-98B8-B5B6FFE03A14Q37381103-0AE2BFBE-155C-4795-A372-D771FC74886EQ37412449-8E4DFEC0-0C28-4505-AE6F-4B0755C2A3FDQ37432455-EC6ABCFE-EFAF-4EEB-B1AF-4BB72F1B7786Q37529665-7CA117C1-6C7E-4839-BD3A-5B8727C61E12Q38289907-38B11B01-B456-48D2-8BF3-1D25B6EFF08EQ38676352-CC40E050-16C6-441A-8DA2-95299E8D8D61Q39377293-1C5CB4D7-8356-405A-B3A7-BC9F93326A1FQ39763546-0A7ACA7D-8BD6-4426-B021-E507BD510B5AQ40623008-795A9978-9E37-499F-A417-81097D2C56C9Q40623865-EFBAB8F7-3230-44F0-BF45-D3770BEC4406Q40872499-B99E4334-27CC-492A-A534-486A036FF4AFQ41062569-57C2FFC7-1FC4-41F9-8F79-890C7D16AEB1Q41112864-3002AA84-BC79-401B-9DDC-B3EAC5ED1FF6Q41233319-AD8288C0-5E64-4F64-896C-150045EAD26DQ41525920-795BAF7F-9FC6-49ED-A0DD-7529273911C3Q41592810-2568A46C-0294-4C3A-9611-BE7AA7D6D4AC
P2860
Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase.
description
1989 nî lūn-bûn
@nan
1989 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1989 թվականի մարտին հրատարակված գիտական հոդված
@hy
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
name
Somatostatin analogues inhibit ...... mulating tyrosine phosphatase.
@ast
Somatostatin analogues inhibit ...... mulating tyrosine phosphatase.
@en
type
label
Somatostatin analogues inhibit ...... mulating tyrosine phosphatase.
@ast
Somatostatin analogues inhibit ...... mulating tyrosine phosphatase.
@en
prefLabel
Somatostatin analogues inhibit ...... mulating tyrosine phosphatase.
@ast
Somatostatin analogues inhibit ...... mulating tyrosine phosphatase.
@en
P2093
P2860
P356
P1476
Somatostatin analogues inhibit ...... mulating tyrosine phosphatase.
@en
P2093
P2860
P304
P356
10.1073/PNAS.86.6.2003
P407
P577
1989-03-01T00:00:00Z